Synopsis
Motivation:
Goals:
Approach:
Results:
362-06-005
ISMRM Abstract
A Connectome Analysis Linking Brain Structure and Pathophysiological Measures Toward Early Alzheimer’s Detection
Accepted
Full abstract & presentation
The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.
Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.
To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.
Log inReferences
1. Breijyeh Z, Karaman R. Comprehensive review on alzheimer’s disease: Causes and treatment. Molecules. 2020 Dec 8;25(24):5789. doi:10.3390/molecules25245789 [doi]
2. Binder LI, Guillozet-Bongaarts AL, Garcia-Sierra F, Berry RW. Tau, Tangles, and alzheimer’s disease. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2005 Jan;1739(2–3):216–23. doi:10.1016/j.bbadis.2004.08.014 [doi]
3. Jack CR, Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A, et al. Revised criteria for diagnosis and staging of Alzheimer’s disease: Alzheimer’s Association Workgroup. Alzheimer’s & Dementia. 2024 Jun 27;20(8):5143–69. doi:10.1002/alz.13859 [doi]
4. Rao YL, Ganaraja B, Murlimanju BV, Joy T, Krishnamurthy A, Agrawal A. Hippocampus and its involvement in Alzheimer’s disease: a review. 3 Biotech. 2022 Feb;12(2). doi:10.1007/s13205-022-03123-4 [doi]
5. Yang Z, Sreenivasan K, Toledano Strom EN, Osse AM, Pasia LG, Cosme CG, et al. Clinical and biological relevance of glial fibrillary acidic protein in Alzheimer’s disease. Alzheimer’s Research & Therapy. 2023 Nov 3;15(1). doi:10.1186/s13195-023-01340-4 [doi]
6. Jack CR, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. The Lancet Neurology. 2013 Feb;12(2):207–16. doi:10.1016/s1474-4422(12)70291-0 [doi]
7. Echávarri C, Aalten P, Uylings HB, Jacobs HI, Visser PJ, Gronenschild EH, et al. Atrophy in the parahippocampal gyrus as an early biomarker of Alzheimer’s disease. Brain Structure and Function. 2010 Oct 19;215(3–4):265–71. doi:10.1007/s00429-010-0283-8 [doi]
8. de Flores R, La Joie R, Chételat G. Structural imaging of hippocampal subfields in healthy aging and Alzheimer’s disease. Neuroscience. 2015 Nov;309:29–50. doi:10.1016/j.neuroscience.2015.08.033 [doi]
9. Sabuncu MR, Desikan RS, Sepulcre J, Yeo BTT, Liu H, Schmansky N, et al. The Dynamics of Cortical and Hippocampal Atrophy in Alzheimer’s Disease. Archives of Neurology. 2011 Aug 1;68(8):1040. doi:10.1001/archneurol.2011.167 [doi]
10. Rich A, Oh H. Distinctive volumetric associations between plasma p-tau181 and hippocampal formation structures across the Alzheimer’s disease continuum. Journal of Alzheimer’s Disease. 2025 Sept;107(2):561–74. doi:10.1177/13872877251361354 [doi]
11. Oliveira M, Bellaver B, Lussier FZ, Ferreira PCL, Povala G, Leffa DT, et al. Hippocampal degeneration is associated with GFAP levels in individuals with vascular dementia independently of amyloidosis. Alzheimer’s & Dementia. 2024 Dec;20(S9). doi:10.1002/alz.094078 [doi]
12. Hu Q, Shi M, Li Y, Zhao X. Elevated plasma neurofilament light was associated with multi-modal neuroimaging features in Alzheimer’s disease signature regions and predicted future Tau deposition. BMC Neurology. 2024 Jul 6;24(1). doi:10.1186/s12883-024-03728-7 [doi]
13. Xu J, Tan S, Wen J, Zhang M, Alzheimer’s Disease Neuroimaging Initiative, Xu X. Progression of hippocampal subfield atrophy and asymmetry in Alzheimer’s disease. European Journal of Neuroscience. 2024 Sept 22;60(8):6091–106. doi:10.1111/ejn.16543 [doi]
Cite this abstract
http://echo.ismrm.org/p/ISMRM2026/362-06-005